Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Evaluation of a diffractive trifocal IOL in patients with previous myopic laser vision correction over a 12-month follow-up period

Search Title by author or title

Session Details

Session Title: Moderated Poster Session: Finding the Right Pseudophakic Presbyopia Treatment

Venue: Poster Village: Pod 2

First Author: : Y.Park SOUTH KOREA

Co Author(s): :                           

Abstract Details

Purpose:

To evaluate 1-year visual outcome and refractive stability of diffractive trifocal intraocular lens (IOL) implantation in patients with prior myopic laser vision correction.

Setting:

Eye Love Eye Clinic, Seoul, South Korea.

Methods:

Retrospective study of 32 eyes of 18 patients with prior myopic laser vision correction who had uncomplicated cataract surgery with the diffractive trifocal AT LISA® tri 839MP (Carl Zeiss Meditec AG, Jena, Germany). Visual acuity measurements were performed for uncorrected near (UNVA at 40cm), intermediate (UIVA, at 80cm) and distance vision (UDVA) at 1, 3, 6 and 12 months. The accuracy of Haigis-L formula was compared to Barrett True-K (no-history) and Shammas formula using an online calculator designed for post-refractive cataract patients.

Results:

Mean age of patients was 52.01±6.24 years. At the 1-year follow-up, UDVA, UIVA and UNVA were 0.74±0.15, 0.54±0.08 and 0.89±0.14 (decimal) respectively. Mean spherical equivalent at 1, 3, 6 and 12 months were -0.90±0.46, -0.93±0.46, -0.87±0.44 and -0.76±0.37. Barrett True-K and Haigis-L formulae had significantly smaller prediction errors compared to Shammas formula with mean refractive prediction errors of -0.27±0.38, -0.20±0.40 and -0.61±0.43 respectively. No patient required postoperative enhancement.

Conclusions:

Trifocal implantation in patients with prior myopic refractive surgery is an excellent option to provide good levels of near, intermediate and distance vision. When choosing the IOL power, Haigis-L and Barrett True-K formula should be considered to provide refractive stability for patients.

Financial Disclosure:

None

Back to previous